All In MedTech

FDA Clearance Tracker · P240013

Sphere-9 Catheter and Affera Ablation System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Oct 24, 2024 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Oct 24, 2024

Approved

Time to decision

196 days

Received Apr 11, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P240013
Device name
Sphere-9 Catheter and Affera Ablation System
Applicant location
Mounds View, MN
Received
Apr 11, 2024
Decided
Oct 24, 2024
Decision
Approved
Supplements
32 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QZI

FDA's approval statement

As written in FDA's record.

approval for the Sphere-9™ Catheter and Affera™ Ablation System. This device is indicated for use in cardiac electrophysiological mapping (stimulation and electrogram recording) and for treatment of drug refractory, recurrent, symptomatic persistent atrial fibrillation (episode duration less than 1 year) and radiofrequency ablation of cavotricuspid isthmus dependent atrial flutter when used with the Affera mapping system.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code QZI. The earliest in FDA's data is P230017, decided Dec 13, 2023.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.